Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.31 |
| ▸ | TYR | P14679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19141648 | 0.73 | — | — | |
| SCHEMBL10282138 | 0.73 | HPGD (0.36) | CRHR1ALDH1A1HTTHIF1A | |
| SCHEMBL12593462 | 0.72 | LMNA (0.54) | CRHR1ALDH1A1GAAALOX12HTT | |
| SCHEMBL9909702 | 0.72 | CRHR1 (0.42) | CRHR1ALDH1A1GAAALOX12HTT | |
| SCHEMBL25481760 | 0.71 | TYR (0.35) | ALDH1A1GAAALOX12HTTHIF1A | |
| SCHEMBL21902397 | 0.71 | ALDH1A1 (0.32) | ALDH1A1GAAALOX12HTTHIF1A | |
| SCHEMBL15984530 | 0.71 | CRHR1 (0.41) | CRHR1ALDH1A1GAAALOX12HTT | |
| SCHEMBL7484629 | 0.71 | ALDH1A1 (0.53) | CRHR1ALDH1A1GAAALOX12HTT | |
| SCHEMBL15614475 | 0.71 | ALOX12 (0.59) | CRHR1ALDH1A1GAAALOX12HTT | |
| SCHEMBL19334606 | 0.71 | LMNA (0.38) | ALDH1A1GAAALOX12HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584748-B2 | Spirocyclic compounds | C4 THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | C4 THERAPEUTICS, INC. (US) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032245-A1 | SPIROCYCLIC COMPOUNDS | CRBN, RBX1, XIAP | CRHR1 3126/4885ALDH1A1 2000/4885GAA 2719/4885 |
| US-11584748-B2 | Spirocyclic compounds | CRBN, RBX1, XIAP | CRHR1 3126/4885ALDH1A1 2000/4885GAA 2719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.